Lilly case id: (b)(4).
This report is associated with product complaint: (b)(4).
This spontaneous case, reported by consumer who contacted the company to report adverse events and a product complaint (pc) with additional information from pharmacist, concerned a female patient of unknown age and ethnicity.
Medical history and concomitant medications were not provided.
The patient began taking insulin lispro (rdna origin) injections (humalog, 100u/ml) from cartridge via a reusable pen (humapen savvio, pink), subcutaneously, for diabetes mellitus (dm) (dose and frequency were not provided), beginning on an unspecified date.
On an unknown date, while being on insulin lispro therapy, she had a circulatory collapse and her blood glucose was out of control (values, units and normal reference range not provided) for which she had been hospitalized on (b)(6) 2020 (reported as during the last weekend).
On an unknown date, she noticed that her humapen savvio (pink) device was broken as the injection screw did not come out and the humapen savvio (pink) did not release insulin lispro (pc no.
(b)(4), lot no.
1405v02).
Further information regarding corrective treatment was not provided.
She got recovered from the event of circulatory collapse while the outcome for remaining event was not reported.
Status of insulin lispro therapy was not provided.
Follow up would not be possible as the reporter denied consent and the treating physician contact details were not provided.
The operator of the humapen savvio (pink) and his/her training status was not provided.
The general humapen savvio (pink) model duration of use and the suspect humapen savvio (pink) model duration of use were not provided.
The action taken with the humapen savvio (pink) was not provided and its return was expected.
The reporting consumer and pharmacist did not provide any relatedness assessment for the events with insulin lispro therapy and humapen savvio (pink) device.
Update 14-aug-2020: information received on 12-aug-2020 and 14-aug-2020 was combined and processed together.
Update 24-aug-2020: additional information was received from pharmacist reporter on 21-aug-2020.
Added pharmacist reporter.
Updated the suspect drug coding to insulin lispro cartridges, product delivered by device and as reported causality for the event of blood glucose abnormal with the suspect humapen savvio (pink) device.
Upon review of the case, updated the indication for use to diabetes mellitus.
Updated the causality statement and narrative with new information.
Edit 27aug2020: updated medwatch european and (b)(6) fields for expedited device reporting.
No new information added.
|